Benchmark Capital Advisors’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | $764K | Hold |
222,700
| – | – | 0.76% | 42 |
|
|
2018
Q3 | $1.34M | Buy |
222,700
+1,000
| +0.5% | +$6.01K | 1.01% | 31 |
|
|
2018
Q2 | $1.41M | Hold |
221,700
| – | – | 1.07% | 30 |
|
|
2018
Q1 | $1.05M | Buy |
221,700
+36,500
| +20% | +$173K | 0.83% | 41 |
|
|
2017
Q4 | $619K | Sell |
185,200
-9,000
| -5% | -$30.1K | 0.48% | 56 |
|
|
2017
Q3 | $416K | Hold |
194,200
| – | – | 0.32% | 78 |
|
|
2017
Q2 | $478K | Hold |
194,200
| – | – | 0.38% | 66 |
|
|
2017
Q1 | $447K | Sell |
194,200
-4,000
| -2% | -$9.21K | 0.35% | 69 |
|
|
2016
Q4 | $194K | Buy |
198,200
+80,000
| +68% | +$78.3K | 0.16% | 107 |
|
|
2016
Q3 | $134K | Buy |
118,200
+58,600
| +98% | +$66.4K | 0.1% | 116 |
|
|
2016
Q2 | $88K | Hold |
59,600
| – | – | 0.07% | 119 |
|
|
2016
Q1 | $85K | Hold |
59,600
| – | – | 0.07% | 113 |
|
|
2015
Q4 | $98K | Sell |
59,600
-10,000
| -14% | -$16.4K | 0.08% | 114 |
|
|
2015
Q3 | $163K | Sell |
69,600
-2,000
| -3% | -$4.68K | 0.13% | 112 |
|
|
2015
Q2 | $195K | Sell |
71,600
-28,000
| -28% | -$76.3K | 0.14% | 114 |
|
|
2015
Q1 | $334K | Sell |
99,600
-500
| -0.5% | -$1.68K | 0.22% | 89 |
|
|
2014
Q4 | $347K | Sell |
100,100
-33,550
| -25% | -$116K | 0.23% | 86 |
|
|
2014
Q3 | $672K | Buy |
133,650
+44,650
| +50% | +$225K | 0.46% | 62 |
|
|
2014
Q2 | $1.23M | Buy |
89,000
+4,000
| +5% | +$55.2K | 0.77% | 49 |
|
|
2014
Q1 | $1.3M | Hold |
85,000
| – | – | 0.9% | 39 |
|
|
2013
Q4 | $687K | Buy |
85,000
+19,500
| +30% | +$158K | 0.48% | 65 |
|
|
2013
Q3 | $653K | Buy |
65,500
+45,500
| +228% | +$454K | 0.47% | 69 |
|
|
2013
Q2 | $85K | Buy |
+20,000
| New | +$85K | 0.07% | 124 |
|